Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Importance of target-mediated drug disposition for small molecules.

Smith DA, van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lavé T, Rowland M.

Drug Discov Today. 2018 Dec;23(12):2023-2030. doi: 10.1016/j.drudis.2018.06.010. Epub 2018 Jun 19. Review.

PMID:
29928850
2.

Impact of target interactions on small-molecule drug disposition: an overlooked area.

van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lavé T, Rowland M, Smith DA.

Nat Rev Drug Discov. 2018 Apr;17(4):299. doi: 10.1038/nrd.2018.26. Epub 2018 Feb 23. No abstract available.

PMID:
29472637
3.

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.

Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N.

Drug Metab Dispos. 2014 Aug;42(8):1301-13. doi: 10.1124/dmd.114.057976. Epub 2014 May 22.

PMID:
24855184
4.

P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.

Lagas JS, Damen CW, van Waterschoot RA, Iusuf D, Beijnen JH, Schinkel AH.

Mol Pharmacol. 2012 Oct;82(4):636-44. Epub 2012 Jul 5.

PMID:
22767610
5.

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD.

J Clin Pharmacol. 2012 Mar;52(3):370-80. doi: 10.1177/0091270010397051. Epub 2011 Apr 19.

PMID:
21505085
6.

An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

ter Heine R, Van Waterschoot RA, Keizer RJ, Beijnen JH, Schinkel AH, Huitema AD.

J Pharm Sci. 2011 Jun;100(6):2508-15. doi: 10.1002/jps.22457. Epub 2010 Dec 29.

PMID:
21491455
7.

A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.

van Waterschoot RA, Schinkel AH.

Pharmacol Rev. 2011 Jun;63(2):390-410. doi: 10.1124/pr.110.002584. Epub 2011 Apr 13. Review.

PMID:
21490128
8.

Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.

van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2010 Dec 15;127(12):2959-64. doi: 10.1002/ijc.25279.

9.

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH.

Br J Pharmacol. 2010 Jul;160(5):1224-33. doi: 10.1111/j.1476-5381.2010.00759.x.

10.

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.

Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Cancer Ther. 2010 Feb;9(2):319-26. doi: 10.1158/1535-7163.MCT-09-0663. Epub 2010 Jan 26.

11.

ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity.

van Waterschoot RA, Eman RM, Wagenaar E, van der Kruijssen CM, Rosing H, Beijnen JH, Schinkel AH.

Clin Cancer Res. 2009 Dec 15;15(24):7616-7623.

12.

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH.

Cancer Res. 2009 Dec 1;69(23):8996-9002. doi: 10.1158/0008-5472.CAN-09-2915. Epub 2009 Nov 17.

13.

Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.

van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH.

Drug Metab Dispos. 2009 Dec;37(12):2305-13. doi: 10.1124/dmd.109.029397. Epub 2009 Sep 14.

PMID:
19752211
14.

How important is intestinal cytochrome P450 3A metabolism?

van Herwaarden AE, van Waterschoot RA, Schinkel AH.

Trends Pharmacol Sci. 2009 May;30(5):223-7. doi: 10.1016/j.tips.2009.02.003. Epub 2009 Mar 28.

PMID:
19328560
15.

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.

Clin Cancer Res. 2009 Apr 1;15(7):2344-51. doi: 10.1158/1078-0432.CCR-08-2253. Epub 2009 Mar 10.

16.

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.

Zimmermann C, van Waterschoot RA, Harmsen S, Maier A, Gutmann H, Schinkel AH.

Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71. doi: 10.1016/j.ejps.2008.12.007. Epub 2008 Dec 24.

PMID:
19138736
17.

Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver.

van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Schinkel AH.

FASEB J. 2009 Jan;23(1):224-31. doi: 10.1096/fj.08-114876. Epub 2008 Sep 15.

PMID:
18794335
18.

P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.

Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH.

Antimicrob Agents Chemother. 2008 Mar;52(3):1034-9. doi: 10.1128/AAC.01041-07. Epub 2008 Jan 14.

19.

Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.

van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH.

Mol Pharmacol. 2008 Mar;73(3):1029-36. Epub 2007 Dec 21.

20.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH.

J Clin Invest. 2007 Nov;117(11):3583-92.

21.

Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.

de Graaf C, Oostenbrink C, Keizers PH, van Vugt-Lussenburg BM, van Waterschoot RA, Tschirret-Guth RA, Commandeur JN, Vermeulen NP.

Curr Drug Metab. 2007 Jan;8(1):59-77.

PMID:
17266524
22.

Topological role of cytochrome P450 2D6 active site residues.

van Waterschoot RA, Keizers PH, de Graaf C, Vermeulen NP, Tschirret-Guth RA.

Arch Biochem Biophys. 2006 Mar 1;447(1):53-8. Epub 2006 Jan 23.

PMID:
16466686

Supplemental Content

Loading ...
Support Center